Genelux Corporation (NASDAQ:GNLX) Receives Average Recommendation of "Buy" from Analysts

Key Points

• Genelux Corporation (NASDAQ:GNLX) has an average rating of "Buy" from five research firms, with four analysts recommending a buy and one a strong buy.
• The average 12-month price target set by analysts for Genelux is $17.75, despite the stock currently trading around $3.34.
• Institutional investors own 37.33% of Genelux shares, with several firms making new acquisitions in the company recently.

Shares of Genelux Corporation (NASDAQ:GNLX - Get Free Report) have earned a consensus recommendation of "Buy" from the five ratings firms that are currently covering the firm, Marketbeat Ratings reports. Four analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $17.75.

Several research analysts have commented on the company. Benchmark cut their price target on Genelux from $25.00 to $23.00 and set a "speculative buy" rating on the stock in a research report on Thursday, May 8th. HC Wainwright reaffirmed a "buy" rating on shares of Genelux in a research report on Wednesday, July 23rd. Finally, Wall Street Zen raised Genelux from a "sell" rating to a "hold" rating in a research report on Saturday, July 12th.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in GNLX. LifeSteps Financial Inc. increased its holdings in shares of Genelux by 13.6% in the second quarter. LifeSteps Financial Inc. now owns 97,219 shares of the company's stock valued at $279,000 after purchasing an additional 11,627 shares during the period. Woodward Diversified Capital LLC increased its holdings in shares of Genelux by 21.7% in the second quarter. Woodward Diversified Capital LLC now owns 1,778,286 shares of the company's stock valued at $5,104,000 after purchasing an additional 317,173 shares during the period. Beacon Capital Management LLC increased its holdings in shares of Genelux by 99.8% in the second quarter. Beacon Capital Management LLC now owns 19,116 shares of the company's stock valued at $55,000 after purchasing an additional 9,550 shares during the period. Falcon Wealth Planning increased its holdings in shares of Genelux by 83.3% in the second quarter. Falcon Wealth Planning now owns 22,000 shares of the company's stock valued at $63,000 after purchasing an additional 10,000 shares during the period. Finally, Goldman Sachs Group Inc. purchased a new stake in shares of Genelux in the first quarter valued at approximately $239,000. Institutional investors and hedge funds own 37.33% of the company's stock.

Genelux Price Performance

Shares of NASDAQ GNLX traded down $0.02 during midday trading on Friday, hitting $3.53. 131,571 shares of the company's stock were exchanged, compared to its average volume of 150,054. Genelux has a twelve month low of $1.60 and a twelve month high of $5.89. The company has a market cap of $133.29 million, a PE ratio of -4.01 and a beta of -0.34. The firm's fifty day simple moving average is $2.97 and its 200-day simple moving average is $3.22.

Genelux (NASDAQ:GNLX - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($0.21) earnings per share for the quarter, topping the consensus estimate of ($0.24) by $0.03. Equities analysts anticipate that Genelux will post -0.88 EPS for the current fiscal year.

Genelux Company Profile

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.